Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.
Ludwig H et al. Br J Haematol. 2015 Jul 7. doi: 10.1111/bjh.13582. [Epub ahead of print].

Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study.
Voorhees PM et al. Br J Haematol. 2015 Jul 22. doi: 10.1111/bjh.13592. [Epub ahead of print].

Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
Martino M et al. Cytotherapy. 2015 Jul 15. pii: S1465-3249(15)00925-1. doi: 10.1016/j.jcyt.2015.05.010. [Epub ahead of print].

Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation.
Pham T et al. Transfusion. 2015 Jul 14. doi: 10.1111/trf.13233. [Epub ahead of print].

Biosimilar filgrastim (Zarzio®) vs. lenograstim (Myelostim®) for peripheral blood stem cell mobilization in adult patients with lymphoma and myeloma: a single center experience.
Marchesi F et al. Leuk Lymphoma. 2015 Jul 18:1-4. [Epub ahead of print].

Reducing Treatment-related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
Pawarode A et al. Biol Blood Marrow Transplant. 2015 Jul 23. pii: S1083-8791(15)00498-X. doi: 10.1016/j.bbmt.2015.07.021. [Epub ahead of print].

Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
Gimsing P et al. Bone Marrow Transplant. 2015 Jun 29. doi: 10.1038/bmt.2015.125. [Epub ahead of print].

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.
San Miguel JF et al. Haematologica. 2015 Jul 9. pii: haematol.2015.125864. [Epub ahead of print].

Dose-adjusted Lenalidomide Combined with Low-dose Dexamethasone Rescues Older Patients with Bortezomib-resistant Multiple Myeloma.
Yamasaki S et al. Intern Med. 2015;54(14):1711-5. doi: 10.2169/internalmedicine.54.4075. Epub 2015 Jul 15.

Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma.
Stöhr E et al. J Cancer Res Clin Oncol. 2015 Jul 9. [Epub ahead of print].

A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Griffin PT et al. Cancer. 2015 Jul 6. doi: 10.1002/cncr.29533. [Epub ahead of print].